Tolerability and efficacy of induction Bacillus Calmette–Guérin for non-muscle invasive bladder cancer
Inability to tolerate BCG occurred in 28% of patients, with 5.9% experiencing discontinuation. Interruptions were short, mostly concerning UTI, and rarely leading to discontinuation. Poor tolerability was associated with male sex, hypertension, and low pre-treatment hemoglobin levels, highlighting critical targets for reducing the risk of BCG interruption or discontinuation.
Authors
- Saum Ghodoussipour (ORCID: https://orcid.org/0000-0001-8901-0210)
- Ellen M. Cahill (ORCID: https://orcid.org/0000-0003-0459-534X)
- Sai Krishnaraya Doppalapudi
- John Pfail (ORCID: https://orcid.org/0000-0002-0856-3348)
- Mann Patel (ORCID: https://orcid.org/0009-0002-0193-6102)
- Thomas L. Jang (ORCID: https://orcid.org/0000-0001-5886-3835)
- David Golombos
- Vignesh T. Packiam (ORCID: https://orcid.org/0000-0001-8397-7797)
- Aravind Rajagopalan (ORCID: https://orcid.org/0000-0002-3162-4655)
- Kevin Chua
- Rachel Passarelli
Institutions
- Robert Wood Johnson University Hospital (US)
- Johnson University (US)
- Yale University (US)
Publication Details
- Journal
- Bladder
- Published
- 2025-04-11
- DOI
- https://doi.org/10.14440/bladder.2024.0051
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00